MedTrace Logo

Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia.

NCT01305694 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2011-03-01

No results posted yet for this study

Summary

The study is a phase I/II trial designed to establish the safety and efficacy of intravenous administration of bone marrow derived mesenchymal stem cells from related donor to patients with relapsed/refractory aplastic anemia.

Conditions

  • Aplastic Anemia

Interventions

BIOLOGICAL

bone marrow derived mesenchymal stem cells

Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks

Sponsors & Collaborators

  • Guangzhou Municipal Twelfth People's Hospital

    collaborator OTHER

  • Guangdong Prevention and Treatment Center for Occupational Diseases

    collaborator OTHER

  • Guangzhou General Hospital of Guangzhou Military Command

    lead OTHER

Principal Investigators

  • Yang Xiao, MD · Guangzhou General Hospital of Guangzhou Military Command

Study Design

Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-06-30
Completion
2012-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01305694 on ClinicalTrials.gov